Skyline will use TrovaGene's nucleophosmin protein mutation, which is found in around 35 percent of acute myeloid leukemia patients and is associated with good disease prognosis, in its Affymetrix-manufactured AMLprofiler in vitro diagnostic.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.
